Detalhe da pesquisa
1.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Int J Cancer
; 151(8): 1335-1344, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603906
2.
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.
Oncologist
; 25(2): e391-e395, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043780
3.
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Sci Transl Med
; 16(731): eadd1834, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266104
4.
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.
Eur J Cancer
; 162: 161-169, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34998048